The startup specializes in target protein degradation technology that transforms undruggable proteins into druggable targets through in-vitro and in-vivo methods. This approach enables the development of personalized small molecule drugs, facilitating the creation of effective treatments for a wide range of diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many disease-causing proteins are considered "undruggable" because traditional small molecule inhibitors cannot effectively bind to their structures or modulate their activity. This limitation hinders the development of treatments for a wide range of diseases where these proteins play a critical role. Existing drug discovery methods often fail to address these challenging targets, leaving a significant unmet need for novel therapeutic approaches.
Solution
FuturedMe is developing a new class of small molecule drugs based on its CANDDY™ platform, which induces the degradation of target proteins rather than inhibiting them. This ubiquitin-independent technology directly targets proteins for proteasomal degradation, leveraging the cell's natural protein disposal machinery. By selectively eliminating disease-related proteins, FuturedMe aims to create personalized medicines that are more versatile and effective than traditional inhibitors. The CANDDY™ platform offers a flexible approach to drug design and profiling, potentially unlocking treatments for previously undruggable targets and expanding the scope of personalized medicine.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for diseases with unmet needs, particularly those involving challenging or previously undruggable protein targets.
Features
- CANDDY™ platform for targeted protein degradation using small molecules
- Ubiquitin-independent mechanism for direct proteasomal degradation
- Versatile drug design and profiling capabilities
- Potential to address previously "undruggable" protein targets
- Personalized medicine approach for tailored treatments